Neurological disorders affecting the central nervous system (CNS) are still incompletely
understood. Many of these disorders lack a cure and are seeking more specific and effective …

The degeneration of forebrain dopamine systems in Parkinson's disease has been an
effective target for pharmaceutical research over the past four decades. However, although …

We have reviewed a battery of useful tests for evaluating sensorimotor function and plasticity
acutely and chronically in unilateral rat models of central nervous system injury. These tests …

In an attempt to define clinically relevant models of akinesia and dyskinesia in 6‐
hydroxydopamine (6‐OHDA)‐lesioned rats, we have examined the effects of drugs with high …

Adult mammalian CNS neurons do not normally regenerate their severed axons. This failure
has been attributed to scar tissue and inhibitory molecules at the injury site that block the …

Previous studies have used recombinant adeno-associated viral (rAAV) vectors to deliver
glial cell line-derived neurotrophic factor (GDNF) in the substantia nigra to protect the nigral …

Rats with unilateral depletion of striatal dopamine (DA) show marked preferential use of the
ipsilateral forelimb. Previous studies have shown that implementation of motor therapy after …

Gene therapy aims to revert diseased phenotypes by the use of both viral and nonviral gene
delivery systems. Substantial progress has been made in making gene transfer vehicles …

As part of a safety and tolerability study, a 65‐year‐old man with Parkinson's disease (PD)
received monthly intracerebroventricular injections of glial‐derived neurotrophic factor …

During the last few years, recombinant viral vectors derived from adenovirus (Ad), adeno-
associated virus (AAV) or lentivirus (LV) have been developed into highly effective vehicles …